Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
Interventions: risperidone, olanzapine, aripiprazole; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 18 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Urinary Tract Infection
Interventions: Fosfomycin tromethamine, Levofloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Sylmar, California • Torrance, California • Decatur, Georgia + 9 more

Conditions: Acute Otitis Externa
Interventions: Ciprodex®, EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension; Drug
Lead sponsor: Exela Pharma Sciences, LLC.; Industry
Eligibility: 6 Months and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 46
States / cities: Birmingham, Alabama • Mesa, Arizona • Jonesboro, Arkansas + 36 more

Conditions: HIV/AIDS
Interventions: Moxifloxacin, Placebo, Efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pouchitis
Interventions: Vedolizumab Placebo, Ciprofloxacin, Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 10
States / cities: Chicago, Illinois • Evanston, Illinois • Minneapolis, Minnesota + 7 more

Conditions: Bipolar Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 28
States / cities: Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more

Conditions: Urinary Tract Infection
Interventions: Ciprofloxacin; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 31
States / cities: Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 25 more

Conditions: Schizophrenia
Interventions: Cariprazine, Aripiprazole, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 17 more

Conditions: Stuttering, Adult
Interventions: Aripiprazole 10 MG, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Community Acquired Pneumonia
Interventions: Zabofloxacin, Levofloxacin 500mg, Zabofloxacin 400mg; Drug
Lead sponsor: IASO Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 13
States / cities: Huntsville, Alabama • Toney, Alabama • Fort Myers, Florida + 10 more

Conditions: Healthy Volunteers
Interventions: LY2484595, Placebo, Moxifloxacin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Daytona Beach, Florida • Evansville, Indiana

Conditions: Hypertension
Interventions: Nebivolol, Atenolol, Moxifloxacin; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alcohol Dependence
Interventions: Placebo, Naltrexone, Naltrexone + Aripiprazole; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Epilepsy
Interventions: BIA 2-093, Moxifloxacin, Placebo; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Non-Cystic Fibrosis Bronchiectasis
Interventions: Ciprofloxacin for Inhalation, Placebo; Drug
Lead sponsor: Aradigm Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 11 more

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Bacterial Conjunctivitis
Interventions: Besivance, Gatifloxacin; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 1 Day to 31 Days
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes
Interventions: Intramuscular olanzapine, aripiprazole, Intramuscular aripiprazole, olanzapine; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Negative Symptoms of Schizophrenia
Interventions: Roluperidone, risperidone, aripiprazole, olanzapine, Placebo; Drug
Lead sponsor: Minerva Neurosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Bellflower, California • Culver City, California • Garden Grove, California + 10 more

Conditions: Phenylketonuria
Interventions: sapropterin dihydrochloride, Moxifloxacin, Moxifloxacin placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Escherichia Coli Infections
Interventions: Levofloxacin, Placebo, Enteroaggregative E. coli (EAEC); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Appendicitis
Interventions: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin, Appendectomy; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,552 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 25
States / cities: Sylmar, California • Torrance, California • Aurora, Colorado + 14 more

Conditions: Schizophrenia
Interventions: Aripiprazole and aripiprazole once-monthly, Paliperidone and paliperidone palmitate; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • San Diego, California

Conditions: Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
Interventions: Aripiprazole Augmentation, Bupropion Augmentation; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: St Louis, Missouri • Pittsburgh, Pennsylvania

Search by objective public record fields.

Metabolic Effects of Antipsychotics in Children

Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)

Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections

Safety and Efficacy of Cariprazine in Patients With Schizophrenia

Dopamine and Sensorimotor Function in Stuttering

Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

A Study of LY2484595 on the Electrical Activity of the Heart

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects

Enteroaggregative E.Coli (EAEC)

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.